drugset
drugset / Trial / NCT03127618

Lorlatinib - PF-06463922

NCT03127618 ↗

Expanded access Approved for marketing Pfizer

Summary

Lorlatinib expanded access program

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Background Lorlatinib Small molecule — —

Indications

No indication recorded.